Our Response to the IV Fluid Shortage

Who can participate?

Inclusion Criteria:

• Patients must be less than 22 years of age at the time of study enrollment

• Patient must have one of the following:

• Patient has known or suspected relapsed/refractory (including primary refractory) AML

• This includes isolated myeloid sarcoma

• Patient has known or suspected relapsed/refractory (including primary refractory) myeloid leukemia of Down syndrome

• Patient has known or suspected relapsed ALL that meets one of the following criteria:

• Second or greater B-ALL medullary relapse, excluding KMT2Ar.

• Any first or greater B-ALL medullary relapse involving KMT2Ar.

• Any first or greater T-ALL medullary relapse with or without KMT2Ar.

• Patient has known or suspected relapsed/refractory (including primary refractory) mixed phenotype acute leukemia

• Patient has known or suspected de novo or relapsed/refractory (including primary refractory) treatment related AML

• All patients and/or their parents or legal guardians must sign a written informed consent

• All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met